AMENDMENT OF THE CLAIMS

26. (Allowed) A method for improving the efficiency of *in vivo* liver cell retroviral transduction, the method comprising, inducing a semi-synchronous wave of *in vivo* liver cell proliferation by concurrently administering tri-iodothyronine (T3) and keratinocyte growth factor (KGF), and further comprising administering to the liver a retroviral vector complexed with cationic liposomes subsequent to the induction of liver cell proliferation, thereby increasing transduction efficiency.

27. (Allowed) The method of claim 26, the cationic liposome comprising DiOctadecylamidoGlycylSpermine (DOGS).

28-50. (Cancelled)

51. (Allowed) A method for treating or preventing cirrhosis of the liver comprising concurrently administering to a subject an effective amount of T3 and an effective amount of KGF, thereby inducing a semi-synchronous wave of liver cell proliferation *in vivo*, and further comprising administering to a liver cell a retroviral vector complexed with cationic liposomes wherein the retroviral vector encodes HGF, which treats or prevents cirrhosis of the liver.

52. (New) The method of claim 51, wherein the effective amount of T3 is ranging from about 400 μg per kg of body weight of the subject to about 40 mg per kg of body weight of the subject.

53. (New) The method of claim 52, wherein the effective amount of T3 is about 4 mg per kg of body weight of the subject.

54. (New) The method of claim 51, wherein the effective amount of KGF is ranging from about 100 μg per kg of body weight of the subject to about 10 mg per kg of body weight of the subject.

55. (New) The method of claim 54, wherein the effective amount of KGF is about 1 mg per kg of body weight of the subject.

56. (New) The method of claim 51, wherein the effective amount of T3 and the effective amount of KGF is in a ratio of about 4:1.

57. (New) The method of claim 56, wherein the effective amount of T3 is in a dose of about 4 mg per kg of body weight of the subject and the effective amount of KGF is in a dose of about 1 mg per kg of body weight of the subject.

58. (New) The method of claim 57, wherein the composition is administered subcutaneously.

59. (New) The method of claim 57, wherein the composition is administered intravenously.

60. (New) The method of claim 57, wherein the composition is administered intramuscularly.

61. (New) The method of claim 57, wherein the composition is administered intraperitoneally.

62. (New) The method of claim 57, wherein the composition is administered directly into the liver.

63. (New) The method of claim 51, the cationic liposome comprising DiOctadecylamidoGlycylSpermine (DOGS).

64. (New) The method of claim 51, wherein the retroviral vector is administered between about 6 hours and 14 days after administration of the composition.

65. (New) The method of claim 51, wherein the retroviral vector is administered between about 24 hours and 8 days after administration of the composition.